OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Slomovitz on the Current Role of PARP Inhibitors in Ovarian Cancer

October 12th 2023

Brian M. Slomovitz, MD, discusses the optimal role for PARP inhibition in patients with ovarian cancer, highlighting its efficacy in those harboring BRCA mutations.

Dr Krill-Jackson on the Practice-Changing Effect of T-DXd in HER2+ Breast Cancer

October 12th 2023

Elisa Krill-Jackson, MD, highlights the practice-changing effects of fam-trastuzumab deruxtecan-nxki in metastatic, HER2-positive breast cancer, as well as whether there is still a role for trastuzumab emtansine in this setting.

Dr Vikas on the Benefit of Utilizing MRD Detection in Breast Cancer Treatment

October 12th 2023

Praveen Vikas, MBBS, discusses the benefits associated with utilizing minimal residual disease detection in breast cancer.

Dr Iams on the Effect of the FLAURA2 Trial in EGFR-Mutant NSCLC

October 12th 2023

Wade T. Iams, MD, discusses the impact of the phase 3 FLAURA2 trial in patients with EGFR-mutant non–small cell lung cancer, highlighting the notable improvements in progression-free survival that the approach elicits.

Dr Hillengass on the Rationale For Investigating the Effect of Exercise on Functional Performance in Multiple Myeloma

October 12th 2023

Jens Hillengass, MD, PhD, discusses the rationale for investigating exercise and its effect on functional performance in multiple myeloma, and highlights the methods utilized in this study.

Dr Allan on the Investigation of Obinutuzumab Triplet Consolidation in MRD-Positive CLL

October 11th 2023

John N. Allan, MD, discusses a planned evaluation of obinutuzumab triplet consolidation therapy for patients with chronic lymphocytic leukemia /small lymphocytic lymphoma who remain minimal residual disease–positive after initial treatment with zanubrutinib and venetoclax .

Dr Kittai on an Indirect Comparison of Acalabrutinib Plus Obinutuzumab vs Zanubrutinib in CLL/SLL

October 11th 2023

Adam Kittai, MD, discusses key findings from a matching-adjusted, indirect comparison of acalabrutinib with or without obinutuzumab vs zanubrutinib monotherapy in treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma.

Dr Stein on Key Considerations When Selecting an Immunotherapy Approach in HCC

October 10th 2023

Stacey Stein, MD, discusses key considerations when selecting a first-line treatment approach for higher-risk patients with hepatocellular carcinoma, and in what scenarios the combination of atezolizumab and bevacizumab is a viable approach in this population.

Dr Hillengass on the Influence of Exercise on Functional Performance in Multiple Myeloma

October 10th 2023

Jens Hillengass, MD, PhD, professor, discusses the influence of physical activity on functional performance for patients with multiple myeloma, according to results from a 2-arm, nonrandomized pilot exercise study.

Dr Brander on Findings From the TRANSCEND CLL 004 Trial in Relapsed/Refractory CLL/SLL

October 10th 2023

Danielle M. Brander, MD, discusses the primary analysis of the phase 1/2 TRANSCEND CLL 004 trial in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Dr Coombs on Switching to Treatment With a BCL-2 Inhibitor Vs a Covalent BTK Inhibitor in CLL/SLL

October 10th 2023

Catherine C. Coombs, MD, discusses the feasibility of switching from treatment with a covalent BTK inhibitor to a BCL-2 inhibitor vs a different covalent BTK inhibitor in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma treated in a real-world setting.

Dr Matous on Factors Influencing Treatment Selection and Sequencing in Multiple Myeloma

October 9th 2023

Jeffrey V. Matous, MD, discusses factors to be considered when determining the optimal sequencing of bispecific antibodies in multiple myeloma.

Dr McLellan on the Association Between A Skin Bacterium and Severe Acute Radiation Dermatitis

October 9th 2023

Beth N. McLellan, MD, discusses the use of a low-cost, topical treatment to prevent severe cases of acute radiation dermatitis potentially caused by the skin bacterium Staphylococcus aureus in breast cancer.

Dr Danilov on the Investigation of BTK Degraders in CLL

October 8th 2023

Alexey Danilov, MD, PhD, discusses the investigation of BTK degraders in the treatment of chronic lymphocytic leukemia.

Dr Woyach on the Prevalence of Mutations in Previously Treated Patients With CLL

October 8th 2023

Jennifer A Woyach, MD, discusses the prevalence of recurrent genomic alterations in apoptotic machinery in patients with previously treated chronic lymphocytic leukemia who were refractory to B-cell receptor pathway inhibitors.

Dr Melenhorst on the Evolving Understanding of CAR T-Cell Therapies in CLL

October 8th 2023

Jan Joseph Melenhorst, PhD, discusses the evolving understanding of the use of CAR T-cell therapies in the treatment of patients with chronic lymphocytic leukemia.

Dr Shadman on Zanubrutinib in CLL/SLL Intolerant to Prior BTK Inhibitors

October 8th 2023

Mazyar Shadman, MD, MPH, discusses preliminary long-term findings from the evaluation of zanubrutinib in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who were intolerant to ibrutinib and/or acalabrutinib.

Dr Feigin on the Effect of Benzodiazepines on Survival Outcomes in Pancreatic Cancer

October 7th 2023

Michael Feigin, PhD, discusses data from a retrospective study investigating the association between benzodiazepines and survival outcomes in patients with pancreatic cancer.

Dr Platzbecker on the COMMANDS Trial in Lower-Risk MDS With Anemia

October 7th 2023

Uwe Platzbecker, MD, discusses key findings from the phase 3 COMMANDS trial with luspatercept in patients with lower-risk myelodysplastic syndrome with anemia, as well as the clinical implications of FDA approval of luspatercept for patients in this population.

Dr Jeselsohn on Enrollment Criteria For the VERITAC-2 Trial in ER+ Breast Cancer

October 7th 2023

Rinath M. Jeselsohn, MD, discusses enrollment criteria for the phase 3 VERITAC-2 trial, as well as the potential clinical implications of this research for patients with advanced estrogen receptor–positive/HER2-negative metastatic breast cancer.